Draft Guidance For Industry On Alzheimer’s Disease: Developing Drugs For The Treatment Of Early Stage Disease; Availability

February 8, 2013
On February 7, 2013, the U.S. Food and Drug Administration (FDA) issued guidance to help companies developing medications for patients with early- stage Alzheimer’s disease before the onset of noticeable dementia symptoms. The FDA sought to clarify how researchers can identify and study patients with very early Alzheimer’s disease. This notice provides infomation about how comments on the draft guidance should be submitted.
Download the Report
;

. . .